PDCD1 and gastric cancer: Prognostic biomarkers, including the neutrophil-to-lymphocyte ratio, have also been proposed, particularly in patients with advanced GC treated with Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) agents [16].